CARISOPRODOL

Course overview

CARISOPRODOL IS AN FDA-APPROVED DRUG INDICATED FOR THE RELIEF OF DISCOMFORT ASSOCIATED WITH ACUTE, PAINFUL MUSCULOSKELETAL CONDITIONS. ALTHOUGH MARKETED AS A MUSCLE RELAXANT, THE PARENT COMPOUND IS CONSIDERED TO BE IN THE TRANQUILIZER CLASS OF MEDICATIONS, WHEREAS THE PRIMARY METABOLITE MEPROBAMATE IS CONSIDERED TO BE IN THE BENZODIAZEPINE CLASS OF DRUGS. THIS ACTIVITY DISCUSSES THE INDICATIONS, MECHANISM OF ACTION, AND CONTRAINDICATIONS FOR CARISOPRODOL AS A VALUABLE AGENT TO RELAX MUSCLES AFTER STRAINS, SPRAINS, AND MUSCLE INJURIES. THIS MEDICATION IS INTENDED TO BE USED TOGETHER WITH REST, PHYSICAL THERAPY, AND OTHER MEASURES. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS (E.G., DOSING, PHARMACODYNAMICS, PHARMACOKINETICS, MONITORING, RELEVANT INTERACTIONS) PERTINENT FOR HEALTHCARE PROFESSIONALS IN THE MANAGEMENT OF PATIENTS WITH MYOFASCIAL PAIN AND RELATED CONDITIONS.